News & Updates
Showing Endocrinology articles
Showing

Glucose level affects immunotherapy efficacy in NSCLC
A study from Israel presented at ELCC 2026 supports the role of glucose control as a modifiable host factor that could improve the effectiveness of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).
Glucose level affects immunotherapy efficacy in NSCLC
02 Apr 2026
Orforglipron: The new kid on the weight loss runway?
The novel oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) orforglipron gains the upper hand over the current leading oral GLP-1 RA, semaglutide, in individuals with type 2 diabetes (T2D) inadequately controlled on metformin in the phase III ACHIEVE-3 study.
Orforglipron: The new kid on the weight loss runway?
31 Mar 2026
Digital intervention plus phentermine-topiramate cuts weight, CVD risk in adults with obesity
Combination treatment with phentermine-topiramate extended release (ER) and a digitally enhanced lifestyle intervention (DELI) results in a significant and sustained weight reduction, as well as a decrease in cardiovascular disease (CVD) risk, in adults with obesity, reports a study.






